Anti-myeloma activity of the novel 2-aminothienopyrimidine Hsp90 inhibitor NVP-BEP800

British Journal of Haematology

Volumn 147, Issue 3, 2009, Pages 319-327

  Stühmer, Thorsten ^a   Chatterjee, Manik ^a   Grella, Evelyn ^a   Seggewiss, Ruth ^a   Langer, Christian ^b   Müller, Sabine ^a   Schoepfer, Joseph ^c   Garcia Echeverria, Carlos ^c   Quadt, Cornelia ^d   Jensen, Michael R ^c   Einsele, Hermann ^a   Bargou, Ralf C ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY HOSPITAL ULM   (Germany)

^c Novartis Institutes for BioMedical Research   (Switzerland)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Molecular haematology; Multiple myeloma; New drugs for lymphoma

Indexed keywords

2 AMINOTHIENOPYRIMIDINE CLASS HSP90 INHIBITOR; BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; HEAT SHOCK PROTEIN 90 INHIBITOR; LENALIDOMIDE; MELPHALAN; NVP BEP 800; UNCLASSIFIED DRUG; VORINOSTAT;

ARTICLE; BONE MARROW CELL; CELL DEATH; CELL LINE; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG EFFECT; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN DEPLETION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW CELLS; CELL DEATH; COCULTURE TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MULTIPLE MYELOMA; NEOPLASM PROTEINS; PYRIMIDINES; STROMAL CELLS; TUMOR CELLS, CULTURED;

EID: 70349906444     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2009.07852.x     Document Type: Article

References (23)

1. Anderson, K.C., Hannah, A.L., Pazdur, R. Farrell, A.T. (2007) A strategic framework for novel drug development in multiple myeloma. British Journal of Haematology, 138, 153 159.
2. Brenner, H., Gondos, A. Pulte, D. (2008) Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood, 111, 2521 2526.
3. Brough, P.A., Barril, X., Borgognoni, J., Chene, P., Davies, N.G.M., Davis, B., Drysdale, M.J., Dymock, B., Eccles, S.A., Garcia-Echeverria, C., Fromont, C., Hayes, A., Hubbard, R.E., Jordan, A.M., Jensen, M.R., Massey, A., Merrett, A., Padfield, A., Parsons, R., Radimerski, T., Raynaud, F.I., Robertson, A., Roughley, S.D., Schoepfer, J., Simmonite, H., Sharp, S.Y., Surgenor, A., Valenti, M., Walls, S., Webb, P., Wood, M., Workman, P. Wright, L. (2009) Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone. Journal of Medicinal Chemistry, 52, 4797 4809.
4. Chatterjee, M., Jain, S., Stühmer, T., Andrulis, M., Ungethüm, U., Kuban, R.-J., Lorentz, H., Bommert, K., Topp, M., Krämer, D., Müller-Hermelink, H.K., Einsele, H., Greiner, A. Bargou, R.C. (2007) STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90α and β in multiple myeloma cells, which critically contribute to tumor-cell survival. Blood, 109, 720 728.
5. Chiosis, G. Neckers, L. (2006) Tumor selectivity of Hsp90 inhibitors: the explanation remains elusive. ACS Chemical Biology, 1, 279 284.
6. Chou, T.-C. (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacological Reviews, 58, 621 681.
7. Eccles, S.A., Massey, A., Raynaud, F.I., Sharp, S.Y., Box, G., Valenti, M., Patterson, L., de Haven Brandon, A., Gowan, S., Boxall, F., Aherne, W., Rowlands, M., Hayes, A., Martins, V., Urban, F., Boxall, K., Prodromou, C., Pearl, L., James, K., Matthews, T.P., Cheung, K.-M., Kalusa, A., Jones, K., McDonald, E., Barril, X., Brough, P.A., Cansfield, J.E., Dymock, B., Drysdale, M.J., Finch, H., Howes, R., Hubbard, R.E., Surgenor, A., Webb, P., Wood, M., Wright, L. Workman, P. (2008) NVP-AUY922: A novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Research, 68, 2850 2860.
8. Gaspar, N., Sharp, S.Y., Pacey, S., Jones, C., Walton, M., Vassal, G., Eccles, S., Pearson, A. Workman, P. (2009) Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells. Cancer Research, 69, 1966 1975.
9. Janz, M., Stühmer, T., Vassilev, L.T. Bargou, R.C. (2007) Pharmacologic activation of p53-dependent and p53-independent apoptotic pathways in Hodgkin/Reed-Sternberg cells. Leukemia, 21, 772 779.
10. Kumar, S.K., Rajkumar, S.V., Dispenziery, A., Lacy, M.Q., Hayman, S.R., Buadi, F.K., Zeldenrust, S.R., Dingli, D., Russell, S.J., Lust, J.A., Greipp, P.R., Kyle, R.A. Gertz, M.A. (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood, 111, 2516 2520.
11. Kyle, R.A. Rajkumar, S.V. (2008) Multiple myeloma. Blood, 111, 2962 2972.
12. Li, Y., Zhang, T., Schwartz, S.J. Sun, D. (2009) New developments in Hsp90 inhibitors as anticancer therapeutics: Mechanisms, clinical perspective and more potential. Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy, 12, 17 27.
13. McCollum, A.K., Lukasiewicz, K.B., Teneyck, C.J., Lingle, W.L., Toft, D.O. Erlichman, C. (2008) Cisplatin abrogates the geldanamycin-induced heat shock response. Molecular Cancer Therapeutics, 7, 3256 3264.
14. Mitsiades, C.S., Mitsiades, N.S., McMullan, C.J., Poulaki, V., Kung, A.L., Davies, F.E., Morgan, G., Akiyama, M., Shringarpure, R., Munshi, N.C., Richardson, P.G., Hideshima, T., Chauhan, D., Gu, X., Bailey, C., Joseph, M., Libermann, T.A., Rosen, N.S. Anderson, K.C. (2006) Antimyeloma activity of heat shock protein-90 inhibition. Blood, 107, 1092 1100.
15. Mitsiades, C.S., Hayden, P.J., Anderson, K.C. Richardson, P.G. (2007) From the bench to the bedside: emerging new treatments in multiple myeloma. Best Practice & Research Clinical Haematology, 20, 797 816.
16. Neckers, L. (2007) Heat shock protein 90: the cancer chaperone. Journal of Biosciences, 32, 517 530.
17. Nimmanapalli, R., Gerbino, E., Dalton, W.S., Gandhi, V. Alsina, M. (2008) HSP70 inhibition reverses cell adhesion mediated and acquired drug resistence in multiple myeloma. British Journal of Haematology, 142, 551 561.
18. San-Miguel, J., Harousseau, J.-L., Joshua, D. Anderson, K.C. (2008) Individualizing treatment of patients with myeloma in the era of novel agents. Journal of Clinical Oncology, 26, 2761 2766.
19. Siegmund, D., Wicovsky, A., Schmitz, I., Schulze-Osthoff, K., Kreuz, S., Leverkus, M., Dittrich-Breiholz, O., Kracht, M. Wajant, H. (2005) Death receptor-induced signaling pathways are differentially regulated by gamma interferon upstream of caspase 8 processing. Molecular and Cellular Biology, 25, 6363 6379.
20. Stühmer, T., Zöllinger, A., Siegmund, D., Chatterjee, M., Grella, E., Knop, M., Kortüm, M., Unzicker, C., Jensen, M.R., Quadt, C., Chène, P., Schoepfer, J., Garcia-Echeverria, C., Einsele, H., Wajant, H. Bargou, R.C. (2008) Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma. Leukemia, 22, 1604 1612.
21. Sydor, J.R., Normant, E., Pien, C.S., Porter, J.R., Ge, J., Grenier, L., Pak, R.H., Ali, J.A., Dembski, M.S., Hudak, J., Patterson, J., Penders, C., Pink, M., Read, M.A., Sang, J., Woodward, C., Zhang, Y., Grayzel, D.S., Wright, J., Barrett, J.A., Palombella, V.J., Adams, J. Tong, J.K. (2007) Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proceedings of the National Academy of Sciences of the United States of America, 103, 17408 17413.
22. Workman, P., Burrows, F., Neckers, L. Rosen, N. (2007) Drugging the cancer chaperone HSP90. Combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Annals of the New York Academy of Sciences, 1113, 202 216.
23. Zhang, H. Burrows, F. (2004) Targeting multiple signal transduction pathways through inhibition of Hsp90. Journal of Molecular Medicine, 82, 488 499.